ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This SpaceSeeking Alpha • 09/08/21
ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational HighlightsGlobeNewsWire • 08/12/21
ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell CarcinomaGlobeNewsWire • 07/28/21
ALX Oncology Holdings Inc. (ALXO) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 07/15/21
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving TodayBenzinga • 07/06/21
ALX Oncology Shares Jump As ALX148 Shows ORR of 72% In Patients With HER2 Positive Stomach CancerBenzinga • 07/06/21
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction CancerGlobeNewsWire • 07/03/21
ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer StudiesGlobeNewsWire • 06/14/21
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction CancerGlobeNewsWire • 06/10/21
ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational HighlightsGlobeNewsWire • 05/17/21
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell CarcinomaGlobeNewsWire • 05/10/21
Alx Oncology Holding Meets 80-Plus Relative Strength Rating BenchmarkInvestors Business Daily • 04/29/21
ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal CancerGlobeNewsWire • 04/21/21
ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148GlobeNewsWire • 04/05/21
ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming MilestonesGlobeNewsWire • 03/18/21
ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer ImmunotherapeuticsGlobeNewsWire • 03/04/21